Dysregulation of the association between tryptamine levels, AHR signalling pathway activation, and MAO activity is observed in Alzheimer’s disease (AD), Parkinson’s disease (PD), autism spectrum disorder (ASD) and schizophrenia. This evidence concerns the gene AHR and Parkinson disease.